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Osteopontin (OPN) was expressed in murine wild-type osteoclasts, localized to the basolateral,
clear zone, and ruffled border membranes, and deposited in the resorption pits during bone
resorption. The lack of OPN secretion into the resorption bay of avian osteoclasts may be a
component of their functional resorption deficiency in vitro. Osteoclasts deficient in OPN were
hypomotile and exhibited decreased capacity for bone resorption in vitro. OPN stimulated CD44
expression on the osteoclast surface, and CD44 was shown to be required for osteoclast motility
and bone resorption. Exogenous addition of OPN to OPN⫺/⫺ osteoclasts increased the surface
expression of CD44, and it rescued osteoclast motility due to activation of the ␣v␤3 integrin.
Exogenous OPN only partially restored bone resorption because addition of OPN failed to
produce OPN secretion into resorption bays as seen in wild-type osteoclasts. As expected with
these in vitro findings of osteoclast dysfunction, a bone phenotype, heretofore unappreciated, was
characterized in OPN-deficient mice. Delayed bone resorption in metaphyseal trabeculae and
diminished eroded perimeters despite an increase in osteoclast number were observed in histomorphometric measurements of tibiae isolated from OPN-deficient mice. The histomorphometric
findings correlated with an increase in bone rigidity and moment of inertia revealed by load-tofailure testing of femurs. These findings demonstrate the role of OPN in osteoclast function and
the requirement for OPN as an osteoclast autocrine factor during bone remodeling.

INTRODUCTION
Osteopontin (OPN) is a phosphorylated glycoprotein synthesized by multiple cell types throughout the body in response to injury and by some cell types as a result of transformation (Sodek et al., 2000; Denhardt et al., 2002; Weber,
2002). In addition, bone cells secrete OPN physiologically
Article published online ahead of print. Mol. Biol. Cell 10.1091/
mbc.E02– 06 – 0354. Article and publication date are at www.molbiolcell.org/cgi/doi/10.1091/mbc.E02– 06 – 0354.
†
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Abbreviations used: ␣v␤3, vitronectin receptors; OPN, osteopontin; OPN⫺/⫺, osteopontin-deficient mice; pQCT, peripheral
quantitative computed tomography; CD44s, standard CD44;
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during the process of skeletal modeling and remodeling,
and it is a major noncollagenous component of bone matrix
(Weinreb et al., 1990; McKee et al., 1993; Takano-Yamamoto
et al., 1994). The sites of OPN deposition in bone include the
lamina limitans at cell-mineralized tissue surfaces, mineralization loci in osteoid, and the organic material at mineralization fronts (McKee et al., 1993; Dodds et al., 1995). Immunolocalization studies have demonstrated OPN in situ in
osteoblasts and have shown its accumulation in mineralized
bone matrix during endochondral and intramembranous
ossification (Reinholt et al., 1990, Hultenby et al., 1991, McKee et al., 1993). Thus, the synthesis, secretion and deposition of OPN in bone remodeling have generally been considered an osteoblast function.
In recent years, multiple investigators have demonstrated
that osteoclasts express the message for OPN (Mark et al.,
1987; Reinholt et al., 1990; Ikeda et al., 1992; Tezuka et al.,
1992; Merry et al., 1993; Takano-Yamamoto et al., 1994;
Dodds et al., 1995) and synthesize the protein (Reinholt et al.,
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1990; Dodds et al., 1995). Dodds et al. (1995) have suggested
that osteoclasts may be the source of OPN in the cement
lines of bone during remodeling. This is in contrast to the
synthesis of OPN by osteoblasts during bone formation. The
debate (McKee and Nanci, 1996) focuses the question of
osteoclast OPN function during bone resorption, which remains unknown despite recent progress.
We have found that avian osteoclasts secrete OPN from
their basolateral cell membranes in vitro, but do not secrete
OPN at the ruffled border or into the resorption cavities
(Chellaiah and Hruska, 2002). Addition of OPN to osteoclast
cultures mimicking secretion from the basolateral surface,
stimulated cell shape changes and cytoskeletal rearrangement observed when cell motility is induced. Although polarized secretion of OPN from the basolateral surface of the
avian osteoclasts aided in its characterization as an autocrine
motility factor, several investigators have shown that OPN is
secreted differently in human osteoclasts, osteoclast-like
cells derived from human giant cell tumors of bone (GCT),
or rodent osteoclasts (Chenu et al., 1994; Maeda et al., 1994;
Dodds et al., 1995). Dodds et al. (1995) have localized OPN to
the resorption pits of osteoclasts in bone and have demonstrated that human GCTs secrete OPN onto the resorption
surfaces of dentine. These results are in agreement with the
studies carried out in rodent osteoclasts (Maeda et al., 1994).
We were able to document this pathway of OPN secretion
into resorption bays of osteoclasts isolated from mice. This
was in contrast to our findings in avian osteoclasts and
demonstrated a species difference in the secretory pathway
of OPN. The lack of OPN secretion into the resorption bay
may be a mechanism for the functional resorption deficiency
of avian cells in vitro (Chellaiah and Hruska, 2002).
OPN contains the arginine-glycine-aspartate (RGD) integrin binding motif, and it functions in cell adhesion related
to the osteoclast integrin ␣v␤3 (Reinholt et al., 1990; Flores et
al., 1992; Ross et al., 1993). OPN is a potent chemotactic factor
acting both as a chemoattractant and as a survival factor
during cell motility (Liaw et al., 1994; Soga et al., 2001). We
have demonstrated that OPN binding to ␣v␤3 activates a
gelsolin-based signal generation complex in osteoclast podosomes that involves Rho activation in the assembly and
disassembly of the osteoclast cytoskeleton during motility
(Chellaiah et al., 2000a). Thus, the functions of OPN in osteoclasts may be the promotion of cell adhesion and chemotaxis during bone resorption (Reinholt et al., 1990; Weber et
al., 1996; Suzuki et al., 2002). However, the absence of a
detected bone phenotype in the original report of OPN
deficiency raises the question as to the importance of osteoclast OPN as an autocrine factor. We have recently discovered a bone phenotype that was originally missed in gelsolin-deficient mice consisting of a mild osteopetrosis
(Chellaiah et al., 2000b). One of the aspects of gelsolin deficiency was the disablement of osteopontin signaling. This
caused us to reconsider the importance of OPN as an osteoclast autocrine factor.
Here, we report that osteoclasts deficient in OPN are
disabled in motility and bone resorption in vitro. Furthermore, we discovered that exogenous OPN rescues cell motility of OPN null osteoclasts, but only incompletely restores
normal bone resorption because exogenous OPN did not
appear in the resorption pit. Also, the surface expression of
CD44 is reduced in OPN⫺/⫺ osteoclasts and exogenous
174

OPN or constitutively active Rho partially restored surface
expression of CD44. An antibody to ␤3 blocked the effect of
OPN. Furthermore, a clear defect in bone resorption was
detected in a complex skeletal phenotype in OPN-deficient
mice. These data demonstrate that OPN is a required osteoclast autocrine mediating CD44 surface expression and
regulating osteoclast motility and bone resorption.

MATERIALS AND METHODS
Materials
Antibodies to the standard (monoclonal and polyclonal) and goat
(polyclonal) anti-human CD44 variant (v3–10; AHS4441) were purchased from BioSource International Inc. (Camarillo, CA). Rabbit
anti-␣v (AB1930) or ␤3 (AB1932) antibodies were purchased from
Chemicon International Inc. (Temecula, CA). Protein assay reagent
kit, reagents for PAGE, and molecular weight standards were purchased from Bio-Rad (Hercules, CA). CY2- or CY3-conjugated antimouse, -rabbit, or -goat antibodies were purchased from Jackson
ImmunoResearch Laboratories, Inc. (West Grove, PA). Biotin (EZlink Sulfo-NHS-LC Biotin) and Immunopure HRP-conjugated
streptavidin were purchased from Pierce (Rockford, IL). Protein A
sepharose, HRP-conjugated mouse, goat, or rabbit IgG, and other
chemicals were purchased from Sigma Chemical Co. (St. Louis,
MO). mCSF1 was purchased from R&D Systems. Inc. (Minneapolis,
MN). pGEX vector containing the cDNA sequences encoding the
RANKL was kindly provided by Dr. Steven L. Teitelbaum (Department of Pathology, Washington University School of Medicine, St.
Louis, MO). RANKL was purified using the glutathione sepharose
(Amersham Biosciences, Piscataway, NJ) as directed by the manufacturers’ instructions.

Osteopontin-deficient Mice
The OPN-deficient mouse colony, originally established at Rutgers
by homologous recombination in ES cells (Rittling et al., 1998), was
rederived at Washington University by caesarian section. The analyses described were performed using wild-type (WT) and osteopontin null (OPN⫺/⫺) mice on a 129 ⫻ C57BL/6 hybrid background.

Coculture and Generation of Murine Osteoclasts In
Vitro
Mouse osteoclasts were generated in vitro using mouse bone marrow cells as described previously (Chellaiah et al., 2001). After 3 d in
culture osteoclasts were generated in cultures supplemented with
mCSF1 (10 ng/ml) and RANKL (55–70 ng/ml). Multinucleated
osteoclasts were observed from day 4 onward. About 90 –95%
TRAP- positive osteoclasts were observed from day 5 onward. To
remove the osteoclasts for in vitro bone resorption or motility
studies, cells were washed with PBS and kept in a cell stripper
solution (Cellgro by Media Tech, Inc., Herndon, VA) for 15–30 min.
Cell stripper is a nonenzymatic cell dissociation solution designed
to gently dislodge adherent cells in tissue culture. After incubation
with the cell stripper solution, osteoclasts were removed from the
plates by gentle scraping. Some of the removed cells were replated
and stained with either trypan blue or for tartrate-resistant acid
phosphatase (TRAP). Cells excluded trypan blue, and they were
99% TRAP positive. These TRAP-positive cells were used for migration and bone resorption assays as described below.

Purification of Osteopontin Protein
Mouse OPN cDNA was cloned into BamHI/XbaI site of pQE 30
vector (Qiagen Inc., Valencia, CA). OPN was expressed as a 6-His–
tagged protein. OPN was purified from the bacterial lysate using
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Ni-NTA affinity chromatography following the manufacturer’s instructions (Qiagen Inc.).

Lysate Preparation and Western Analysis
Purification and transduction of Tat-fusion proteins into osteoclasts
were performed as described previously (Chellaiah et al., 2000 b).
After treatments with Tat fusion proteins or OPN, cells were
washed three times with ice-cold phosphate-buffered saline (PBS)
and added with RIPA lysis buffer (10 mM Tris-HCl, pH 7.2, 150 mM
NaCl, 1% deoxycholate, 1% Triton X-100, 0.1% SDS, 1% aprotinin,
and 2 mM PMSF; Chellaiah and Hruska, 1996). Cells were rocked on
ice and transferred to Eppendorf tubes. The lysates were centrifuged at 15,000 rpm, and the supernatant was saved. Protein contents were measured using the Bio-Rad protein assay reagent kit.
Equal amounts of lysate proteins from WT and OPN⫺/⫺ osteoclasts were used for immunoprecipitation and Western analysis
with anti-CD44 antibody (Chellaiah and Hruska, 1996).

Biotinylation
After 4 or 5 d in culture, the osteoclast precursors made from WT or
OPN⫺/⫺ mice were kept in serum-free media for 2 h. Subsequently, each plate was treated with TAT proteins or OPN as
described above. Cells were washed with PBS and labeled with
biotin according to the manufacturer’s guidelines (Pierce, Rockford,
IL). Briefly, osteoclasts were incubated with 0.5 mg/ml biotin for
30 – 40 min at room temperature. Cells were washed two or three
times with cold PBS and lysed with RIPA buffer (Chellaiah and
Hruska, 1996). Equal amount of proteins were used for immunoprecipitation with a polyclonal CD44 antibody (Biosource International Inc., Camarillo, CA). The immune complexes were subjected
to SDS-PAGE, and the proteins were transferred to a PVDF membrane for immunoblot analyses. Blots were blocked with 10% milk
in PBS containing 0.5% Tween (PBS-T) for 2–3 h and then incubated
with a 1:500 dilution of peroxidase-conjugated streptavidin for over
night at 4°C. After three washes for 10 min each with PBS-T, protein
bands were visualized by chemiluminescence using the ECL-kit
(Pierce).

Cell Migration Assays
Phagokinesis and chemotaxis (transwell migration) assays were
performed as described (Takaishi et al., 1995; Chellaiah et al., 2000b).
For phagokinesis assay, substrates such as recombinant mouse
OPN, vitronectin (VN), or fibronectin (FN) were diluted in PBS and
used for phagokinesis assays, which were performed in six-well
tissue culture dishes. Colloidal gold particles were made essentially
as described (Takaishi et al., 1995). Osteoclasts were seeded at low
density, and the test substance was added as a soluble protein
(OPN, 25 g/ml; VN, 10 g/ml; GRGDS, 50 g/ml) to the ␣-MEM
medium containing 1% serum and 2% BSA. Some wells were
treated with an antibody to OPN, ␤3, or CD44 (25 g/ml) in addition to OPN protein. Osteoclasts phagocytized the colloidal gold
particle during migration and generate white tracks free of the gold
particle. Areas were measured after 14-h incubation with the indicated proteins at 37°C. The migrating cells were visible as a black
body. Cell motility was evaluated by measuring the areas free of
gold particles. By using a grided reticle (Boyce Scientific, Inc., Gray
Summit, NC) in the eyepiece of a Nikon microscope, areas free of
gold particles were measured using a 10⫻ objective and represented
as area moved in mm2.
To assay chemotaxis migration, transwell chambers with membranes of 8-m pore size (Costar, Cambridge, MA) were used
(Senger et al., 1996). The undersides of the membranes were coated
with vitrogen 100 (collagen type 1; 30 mg/ml) at room temperature
for 2 h, as directed by the manufacturer’s instructions. Cells were
added to the upper chamber in ␣-MEM medium containing 1%
serum and 2% BSA (100 l) and the test substrate (OPN, 25 g/ml;
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VN, 10 g/ml; GRGDS, 50 g/ml) was added to the lower chamber
in the same medium (600 l). Antibody to OPN, CD44, or ␤3 (25
g/ml) was added to the upper chamber. Cell migration was allowed to proceed at 37°C in a standard tissue culture incubator for
12–14 h. Cells that migrated to the undersides were stained for
tartrate-resistant acid phosphatase and visualized and counted in a
Nikon microscope using a 10⫻ objective. Data are presented as the
number of migrated cells/field (mean ⫾ SE), and all assays were
performed in quadruplicates. Statistical significance was calculated
as mentioned below in data analysis.

Bone Resorption Assay
Bone resorption assay was performed as described previously
(Chellaiah et al., 2000b). The osteoclast suspension (2 ⫻ 104 cells)
was added to each well and after 2 h of adherence, the culture
medium was replaced with ␣-MEM medium containing either TATfusion proteins as indicated in Figure 8 to a final concentration of
100 nM or OPN (10 g/ml). Some wells were added with an
antibody to OPN, CD44, or integrin ␣v or ␤3 (10 –25 g/ml) and
OPN protein (25 g/ml). Medium was replaced with the respective
protein or antibody after 24 h. After 48 h, cells were scrapped from
dentine and the slices were washed two times with water. Dentine
slices were stained with acid hematoxylin (Sigma) and washed with
water. Pits were viewed under 40⫻ objective in a phase contrast
microscope and photographed.

Immunostaining
Osteoclasts cultured on whale dentine slices or glass coverslips were
immunostained with the indicated antibodies in the results section
as described (Chellaiah et al., 1996, 2000b). To visualize the surface
expression of CD44, osteoclasts were fixed with paraformaldehyde,
rinsed with cold PBS, and incubated with a mAb to CD44 antibody
(1:100 dilution) for 2–3 h without permeablization with Triton
X-100. Cells were washed and counterstained with Cy2- or Cy3conjugated secondary antibodies for 2 h. After washing few times
with PBS, osteoclasts were mounted on a slide in a mounting
solution (Vector Laboratories, Inc., Burlingame, CA). The immunostained cells were viewed and photomicrographed on a Zeiss LSM
410 confocal laser-scanning microscope (Thornwood, NY). CY2 and
CY3 images were recorded using the 488 nm and 568 argon excitation lines, respectively. The background (bone) is shown by the
reflected light in red (pseudocolor) in Figure 1A (bottom panel).
CY2- and CY3-labeled proteins were imaged with dual fluorescence
mode. Images were stored in TIF image format and processed by the
Adobe Photoshop software program (Adobe Systems, Inc., Mountain View, CA).

pQCT Measurement of the Femoral Bone Density
and Area of WT and OPNⴚ/ⴚ Mice
Bone density and area were calculated using a peripheral quantitative computed tomography system (pQCT; Norland Medical Systems, White Plains, NY). Two sections (0.5 mm beam width) were
scanned immediately distal to the growth plate of the femoral head.
Trabecular bone was defined as having a density of between 270
and 630 mg/ml. Cortical bone of the metaphysis was defined as
having a density above 630 mg/cm3. The area and average density
of cortical and trabecular bone from the two sections was calculated
using these parameters and averaged.

Bone Histomorphometry
The tibia were fixed in phosphate-buffered 10% formalin, pH 7.4,
and decalcified in 14% EDTA for 10 –14 d. Bones were washed
sequentially with 50, 70, and 90% ethanol and embedded. longitudinal sections of 5-m thickness were made and stained with TRAP
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Figure 1. Distribution of OPN
and ␣v␤3 integrin in resorbing murine osteoclasts. (A) Top: Osteoclasts plated on bone were immunostained with an antibody to ␤3
integrin (green) and OPN (red) and
analyzed by confocal laser scanning microscopy. The diagonal
white line indicates where the XZ
scan (bottom panel) was made. Bar,
25 m. Bottom: Lateral (XZ) confocal view of the osteoclast shown at
the top. Basolateral membrane
(BLM), and resorbed area are indicated by arrows. Colocalization
(yellow) of OPN and ␣v␤3 was seen
at the basolateral and ruffled border membranes. The bone is shown
by the reflected light in red
(pseudocolor). Asterisk (*) indicates the bone surface. (B) Distribution of OPN and actin in osteoclasts
plated on glass coverslips. Osteoclasts plated on glass coverslips
were immunostained with antiOPN(green)andstainedwithrhodamine phalloidin for actin (red).
Cells were viewed by confocal microscopy. Bar, 25 m.

staining to identify osteoclasts. To estimate mineral apposition rate
and bone formation rate, mice were injected with calcein at 2 and 7 d
before sacrificing. The right distal femur was kept in 90% ethanol
and embedded. Longitudinal sections were made. Static and dynamic histomorphometric measurements were made using a computer and digitizer tablet (Osteomeasure; Osteometrics Inc., Atlanta,
GA) interfaced to a Leitz microscope (Leitz, Wetzlar, Germany) with
a drawing tablet. All measurements were done to the metaphyseal
region distal to the growth plate region. To estimate bone formation
rate, double-labeled and single-labeled areas were traced and calculated as described (Jilka et al., 1996; Weinstein et al., 1997). Terminology used is that recommended by the Histomorphometry
Nomenclature Committee of the American Society of Bone and
Mineral Research (Parfitt et al., 1987).
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Mechanical Testing of Femurs from OPNⴙ/ⴙ and
OPNⴚ/ⴚ Mice
Left femora from WT and OPN⫺/⫺ mice were designated for
biomechanical testing. Femora were isolated, cleaned of soft tissues,
wrapped in gauze that was soaked with PBS, wrapped again in
plastic, placed in a sealed vial, and stored at ⫺20°C until testing.
Before testing, specimens were thawed to 23°C. Four-point bending
tests were conducted using materials testing machine (Comten Industries, Penellas Park, FL) fitted with an appropriate load transducer (400 N force cell, Comten Industries) and linear variable
differential transformer (LVDT; G. L. Collins, Long Beach, CA) for
displacement measurement. Tests were conducted using a fourpoint fixture with 9-mm spacing between the outer (support) points
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and 5-mm spacing between the inner (loading) points. The bones
were flexed in the anterior-posterior plane. The inner points were
displaced at a constant rate of 0.1 mm/s. Force-displacement data
were collected using a computerized data acquisition system (software written by Neil Kizer, analog to digital converter from BSOFT
Software (Columbus, OH).
After testing, force values (F) from the bending tests were converted to bending moment values (M) using the relation M ⫽ Fa/2,
where a was the distance between the outer and inner points (2.0
mm). Normalized displacement (Nd) was calculated by dividing
displacement at the loads by the geometric factor {(3aL ⫺ 4a2)/6} to
allow direct comparison between other experiments done using
different testing geometry’s. L is the distance between outer points
a (9.0 mm) resulting in a correction factor for our geometry of 6.333.
After normalization Nd ⫽ Fa/EI, which can be calculated for any
4-point bending geometry. In the preceding equation E is the elastic
modulus and I is the cross-sectional moment of inertia. From the
moment vs. normalized displacement curves four parameters were
computed: ultimate moment (Nmm), bending rigidity (Nmm2), displacement at failure (mm/mm2) and energy to failure (Nmm*[mm/
mm2]). Failure was defined at the point of ultimate (maximum)
moment, and bending rigidity was defined as the slope of the linear
region of the curve. The elastic modulus (Young’s modulus) was
calculated by dividing the four-point bending rigidity by the crosssectional moment of inertia (I) at the midpoint of the diaphysis. This
calculation is the equivalent of finding the slope of the stress vs.
strain curve. The moment of inertia was determined by analysis of
pQCT images using the Section Maker software package (Formation
Design Systems, Fremantle, WA 6959, Australia).

Data Analysis
All comparisons were made as “% control,” which refers to vehicletreated cells. The other treatment groups in each experiment were
normalized to each control value. Data presented are means ⫾ SEM
of experiments done at different times normalized to intraexperimental control values. For statistical comparisons, analysis of variance (ANOVA) was used with the Bonferroni corrections (Instat for
IBM, version 2.0; Graphpad Software, San Diego, CA)

RESULTS
Cellular Localization of OPN and Integrin ␣v␤3 in
Resorbing Osteoclasts
The ␣v␤3 integrin was previously shown to localize in the
osteoclast plasma membrane opposite to the bone matrix, in
the ruffled border (Lakkakorpi and Vaananen, 1991; Zhao et
al., 2001) and in the clear zone of osteoclasts (Flores et al.,
1992; Hughes et al., 1993; Nesbitt et al., 1993; Nakamura et al.,
1996). Therefore, OPN costaining with integrin ␤3 was performed in mouse osteoclasts plated on dentine slices to
localize OPN staining at the different membrane domains of
resorbing osteoclasts. OPN (red) staining was detected at the
basolateral surface (Figure 1A, top panel) and ruffled border
regions (Figure 1A, bottom panel) of osteoclasts. Basolateral
surface OPN staining (red) was punctate and colocalized
(yellow) with ␤3 (green) in some areas. The diagonal white
line in the top panel of Figure 1 indicates location of the XZ
scanning. In the lateral view of the osteoclast in the XZ scan
(bottom panel), punctate areas of colocalization of ␤3 and
OPN were observed at the basolateral surface and diffuse
OPN staining was observed in the area of resorption (perhaps in the ruffled border). The white line outlines the
resorbed area. The bone is shown by the reflected light in red
(pseudocolor).
Vol. 14, January 2003

The localization of OPN was also analyzed in osteoclasts
plated on glass coverslips. To demonstrate the localization
of OPN in the clear zone area of osteoclasts, OPN distribution was compared with the localization of actin. Punctate
OPN (green) staining was seen throughout the cell, and both
actin and OPN staining were observed at the periphery in
the clear zone area where podosomes are located. The significance of colocalization (overlay) of OPN (green) with
actin (red) at the periphery in the clear zone area (Figure 1B)
of osteoclasts is not known.
Because immunostaining for OPN was observed at the
ruffled border of mouse osteoclasts, it was critical to determine whether the OPN expressed at the ruffled border surface was deposited in the resorption pit. After osteoclasts
were removed, dentine slices were immunostained using an
antibody to OPN. In Figure 2A, serial 2-m sections of
resorption pits generated by osteoclasts derived from WT
mice were taken beginning at the dentine surface (0 m) and
progressing through to the bottom of the deepest pit (52
m). OPN is not present in dentine, and the immunostaining of dentine alone was negative. Dentine slices cultured
with osteoclasts demonstrated positive staining for OPN in
the resorption pits, indicating OPN to be of osteoclast origin.
OPN deposition was seen up to the 48-m section of the
deep pit (Figure 2A). The pit was broader at the surface and
narrowed at the bottom. OPN staining followed the contour
of the pit. Staining intensity was greater at the top and less
intense at the 48-m depth (indicated by arrow). Enlarged
views of resorption pits at 4 and 16 m are shown in Figure
2B. OPN staining was observed both at the rim at 4-m
section (indicated by arrows) as well as at the shoulder-like
structure in the deep resorption pit section at 16-m depth
and the bottom of the other pits (arrows).

In Vitro Bone Resorption Assays
Because addition of soluble OPN stimulated changes in cell
shape, cytoskeletal rearrangement, motility, and bone resorption in osteoclasts isolated from chicken and WT mice
(Chellaiah et al., 2000a, 2000b), osteoclasts isolated from
OPN-null mice were subjected to bone resorption and motility assays in the presence and absence of OPN. OPN was
added as soluble protein to the culture medium.
Osteoclasts derived from WT and OPN⫺/⫺ mice were
plated on dentine slices and treated with PBS (vehicle) or
OPN. The resorption pits generated by osteoclasts derived
from OPN⫺/⫺ mice were very small (Figure 3, C and G)
compared with osteoclasts from WT mice (Figure 3, A and
E). OPN treatment restored the formation of multiple overlapping pits (Figure 3, D and H), which is produced by the
simultaneous process of motility and resorption, to the levels observed in pits produced by WT osteoclasts (Figures 3,
B and F). The depth (XZ scan) and area (XY scan) of the pits
were assessed by confocal microscopy (Table 1). The pits
produced by OPN⫺/⫺ osteoclasts were superficial despite
the addition of OPN (Figures 3H; Table 1), whereas OPN
treatment stimulated pit area and pit depth in osteoclasts
derived from WT mice (Figure 3F; Table 1) in agreement
with our previous reports (Chellaiah et al., 2000b). Although
the increase in pit depth was significant in OPN-treated WT
osteoclasts compared with OPN⫺/⫺ osteoclasts, there were
no significant differences in the pit area. The observations
made in Figure 3 were consistent across multiple osteoclast
177
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Figure 2. Distribution of OPN in
dentine slices from which osteoclasts have been denuded. (A) A
series of 2-m YZ scans of the
deepest resorption pit is shown.
OPN staining is seen up to 48-m
section. Arrows (white) point to
OPN localization. (B) Higher magnification of the sections demonstrates OPN staining at the rim (4
m) and at the shoulder areas of
the resorption pit (16 m). Arrows
(white) point to OPN localization
at the rim in 4 m, within the pit in
16-m sections and at the bottom
of the other pits. The results represent one of three experiments performed.

preparations, all demonstrating significant reductions in pit
depth using osteoclasts from OPN⫺/⫺ mice (Table 1). OPN
addition to OPN⫺/⫺ osteoclasts on dentine slices did not
restore OPN to the surface of the pits, demonstrating that the
added protein did not have access to the resorption space.
Therefore, the OPN staining observed on the resorption
surfaces (Figure 2) was most likely due to secretion from the
ruffled border (Figure 1). These experiments demonstrate
that deposition of OPN into the resorption pits enhances
178

bone resorption and that its deficiency decreases bone resorption.

Motility Studies
To analyze whether OPN serves as critical ligand for osteoclast motility, we performed phagokinesis and transwell
migration assays. Nondirectional osteoclast motility in response to OPN was analyzed by phagokinesis assays as
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Figure 3. The effect of OPN on the bone resorption
of WT and OPN⫺/⫺ osteoclasts. Confocal microscopy analysis of the resorption pits on dentine slices.
(A, B, E, and F) Wild-type osteoclasts; (C, D, G, and
H) OPN-deficient osteoclasts. (A, C, E, and G) Osteoclasts treated with PBS (control); (B, D, F, and H)
osteoclasts treated with OPN. (A–D) Lower power
view of resorption pits using 10⫻ objective. (E–H)
Higher power magnification of resorption pits using
60⫻ objective. Bar, 25 m.

described in MATERIALS AND METHODS. Unstimulated
osteoclasts derived from OPN⫺/⫺ mice were significantly
less motile than WT (Figure 4A). OPN stimulated migration
Vol. 14, January 2003

significantly in osteoclasts isolated from both WT (solid
bars) and OPN⫺/⫺ (open bars) mice. The increase in migration stimulated by OPN in WT osteoclasts was 2.5-fold,
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Table 1. Quantitation of resorption pits generated in vitro by osteoclasts from WT and OPN⫺/⫺ mice
WT

Pit area (m2)
Pit depth (m)

OPN⫺/⫺

PBS

OPN

PBS

OPN

875 ⫾ 128
11.5 ⫾ 2.1c

3782 ⫾ 563a
38.7 ⫾ 3.6d

228 ⫾ 78
3.5 ⫾ 0.35

3228 ⫾ 317b(a)
3.97 ⫾ 0.74

About 10 –15 pits/slice and three slices from each experiment were quantitated. Data are means ⫾ SE of three experiments.
a
p ⬍ 0.001; OPN of WT and OPN⫺/⫺ osteoclasts versus PBS of WT osteoclasts.
b
p ⬍ 0.0001-OPN versus PBS of OPN⫺/⫺ osteoclasts.
c
p ⬍ 0.05; PBS of WT versus PBS and OPN of OPN⫺/⫺ osteoclasts.
d
p ⬍ 0.001; OPN versus PBS of WT osteoclasts.

and in OPN⫺/⫺ osteoclasts, it was 15–20-fold compared
with the respective vehicle (PBS)-treated control osteoclasts.
A 3–5-fold increase in osteoclast motility was observed in
VN- or GRGDS-treated OPN⫺/⫺ osteoclasts, whereas
GRGDS or VN did not significantly increase the motility in
WT osteoclasts. Anti-OPN antibodies significantly decreased phagokinetic movement in both WT and OPN⫺/⫺
osteoclasts, which was not rescued by VN in WT cells. The
reduction in motility below the basal level observed with
PBS in the presence of neutralizing antibody to OPN indicates that basal rates of osteoclast motility are related to
OPN secretion. The addition of anti-CD44 antibody also
significantly inhibited OPN-stimulated phagokinesis.
Directional movement of osteoclasts toward chemoattractants was analyzed using transwell chambers. Filters of
transwell chambers were coated with type I collagen, and
chemotactic substrates were added to the lower chamber as
indicated in Figure 4B. The migration rate with PBS in the
lower chamber of OPN⫺/⫺ osteoclasts was significantly
lower than that of WT osteoclasts. Even though osteoclasts
from OPN⫺/⫺ mice responded to chemotactic factors in the
lower chamber, the rate of migration related to WT osteoclasts was much lower. Thus, the OPN-deficient osteoclasts
were clearly hypomotile. Neutralizing antibodies to ␣v␤3
and CD44 receptors produced results similar to anti-OPN
antibodies.

Effects of OPN Deficiency on CD44 Expression
Because an interaction between CD44 and OPN has been
suggested during chemotaxis (Weber et al., 1996), we analyzed whether OPN deficiency affected CD44 expression.
Immunostaining and confocal microscopy analysis of the
distribution of CD44 protein in WT and OPN⫺/⫺ osteoclasts are shown in Figure 5. The osteoclasts were immunostained before (Figure 5, B and D) and after (Figure 5, A
and C) permeabilization with Triton X-100. Significant differences in the distribution of CD44 between WT and
OPN⫺/⫺ osteoclasts were discovered. A punctate dense
basolateral membrane cell surface expression was observed
in osteoclasts derived from WT mice (Figure 5B), which was
markedly diminished in osteoclasts from OPN⫺/⫺ mice
(Figure 5D). In Triton-permeablized cells, there were no
changes in the intensity of CD44 expression in osteoclasts
derived from WT (Figure 5A) or OPN⫺/⫺ (Figure 5C) mice.
Dense CD44 staining was seen at the perinuclear region as
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Figure 4. The effect of OPN on the motility of WT (f) and
OPN⫺/⫺ (䡺) osteoclasts. Motility of osteoclasts was assessed in
vitro during both phagokinesis (A) and chemotaxis (B) assays. The
treatments (OPN, 25 g/ml; VN, 10 g/ml; GRGDS, 50 g/ml) are
indicated at the bottom of the figures. Some cells were treated with
an antibody to OPN, CD44, or integrin ␤3 (50 g/ml) and OPN
protein (25 g/ml). The data are means ⫾ SE (n ⫽ 3). ***p ⬍ 0.0001
vs. PBS; **p ⬍ 0.001 vs. OPN; *p ⬍ 0.01 vs. OPN.
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Figure 5. Immunolocalization of CD44 in osteoclasts isolated from
WT (A and B) or OPN⫺/⫺ (C and D) mice. Immunostaining with
an antibody to CD44 was performed in Triton-permeablized (A and
C) or nonpermeablized (B and D) osteoclasts. The results represent
one of three experiments performed. Bar, 25 m.

well as at the periphery of the cell closer to the plasma
membrane in both WT (Figure 5A) and OPN⫺/⫺ (Figure
5C) osteoclasts. These data correlated well with the results
shown in Western analyses (Figure 6). Immunostaining for
␣v or ␤3 integrins demonstrated similar levels in osteoclasts
from both WT and OPN⫺/⫺ mice (unpublished data).

Effects of OPN Deficiency on ␣v␤3 and CD44
Expression
Because OPN deficiency decreased surface expression of
CD44, we analyzed the expression levels of integrin ␣v␤3
and CD44 in WT and OPN⫺/⫺ osteoclasts. Osteoclasts
isolated from OPN⫺/⫺ (Figure 6A, lanes 1, 3, 5, and 7) and
WT (lanes 2, 4, 6, and 8) mice were surface-labeled with
biotin and immunoprecipitated with either anti-␤3 (lanes
1and 2) or CD44 antibodies (lanes 5 and 6). Immunoprecipitates were blotted with streptavidin-HRP to visualize the
surface expression of the receptors. Osteoclasts from
OPN⫺/⫺ mice had significantly decreased levels of CD44
surface expression (Figure 6A, lane 5), whereas the surface
expression of integrin ␤3 was the same in both OPN⫺/⫺
(lane 1) and WT (lane 2) osteoclasts. To measure the cellular
levels of CD44, the CD44 immunoblot (lanes 5 and 6) was
stripped and blotted with an antibody to CD44. There were
no changes in the cellular levels of CD44 in OPN⫺/⫺ (lane
7) or WT (lane 8) osteoclasts, and only a single band of
85-kDa CD44 protein was detected. The 85-kDa standard
CD44 (sCD44) protein is the smallest CD44 molecule lacking
the entire variable region (Naot et al., 1997), and sCD44 has
a ubiquitous expression pattern.

Effects of OPN on CD44 Expression
The ability of OPN to stimulate CD44 surface expression
was also examined in osteoclasts isolated from WT and
Vol. 14, January 2003

OPN⫺/⫺ mice. Osteoclasts were treated with PBS or OPN
and surface labeled with biotin. The lysates were subjected
to immunoprecipitation using an antibody to CD44. Immunoprecipitates were blotted with streptavidin-HRP to visualize the surface expression of receptors (Figure 6B, top
panel). Osteoclasts from OPN⫺/⫺ mice showed significantly decreased basal levels of CD44 surface expression and
OPN stimulated surface expression of CD44 in both WT
(lane 2) and OPN⫺/⫺ (lane 4) osteoclasts. The blot shown in
the top panel was stripped and immunoblotted with an
antibody to CD44 to demonstrate the cellular levels of CD44
immunoprecipitated (Figure 6B, bottom panel). Only minor
changes were observed in the cellular level of CD44 in PBS
(bottom panel; lanes 1and 3) or OPN-treated (lanes 2 and 4)
osteoclasts isolated from OPN⫺/⫺ (lanes 3 and 4) or WT
mice (lanes 1 and 2). In fact, more cellular CD44 protein was
immunoprecipitated in both PBS- and OPN-treated osteoclasts isolated from OPN⫺/⫺ mice.
These data are consistent with the significantly decreased
levels of CD44 surface expression in osteoclasts from
OPN⫺/⫺ mice demonstrated in Figure 6A (lane 5), Figure
5D, and in studies designed to detect the presence of variant
forms of CD44 (Figure 6C). To further confirm the expression of standard CD44 in osteoclasts, lysates were made
from osteoclasts (Figure 6C, lanes 2, 3, 5, and 6) and melanoma cells (M21), a positive control for CD44 variants (lanes
1 and 4). Immunoprecipitates were prepared using antibodies to CD44s (lanes 1–3) or CD44 v3–10 (lanes 4 – 6). The
higher molecular weight variant forms of CD44 were detected by a CD44 v3–10 antibody (BioSource International
Inc.). We were unable to detect variant CD44 forms in osteoclasts (lanes 2, 3, 5, and 6) despite their detection in the
positive control melanoma cells (M21; Figure 6C, lanes 1 and
4). The protein bands recognized by this antibody range
from 85 to 250 kDa in melanoma cells, depending on glycosylation and the splice variant form of CD44 (indicated by
asterisks). Results exactly similar to the data in Figures 5 and
6 were observed in four separate osteoclast preparations.

Role of Rho on CD44 Expression
CD44 and Rho-A are physically associated in vivo, and
CD44 bound Rho A displays GTPase activity, which can be
inhibited by C3-mediated ADP-ribosylation (Bourguignon et
al., 1999). We recently reported that transduction of constitutively active Rhoval14 mimicked stimulation of osteoclast
podosome assembly, motility, and bone resorption by OPN
(Chellaiah et al., 2000a). Therefore, we first examined
whether activation of Rho by OPN occurred. After osteoclasts were treated with various treatments as indicated in
Figure 7, surface biotinylation experiments was performed
as described in MATERIALS AND METHODS. Results from
a typical immunoblot of CD44 immunoprecpitates are
shown in A and B. Figure 7A demonstrates the levels of
surface expression of CD44 after various treatments. Treatment of osteoclasts with OPN stimulated CD44 surface expression both in OPN⫺/⫺ (Figure 7A, lane 2) and WT
(Figure 7A, lane 6) osteoclasts. Osteoclasts transduced with
constitutively active RhoVal14 mimic the effects of OPN in
both OPN⫺/⫺ (lanes 3) and WT (lanes 7) osteoclasts,
whereas the dominant negative RhoAsn19 (lane 9) did not
have any effect on the increase in the CD44 surface expression. The Rho inhibitor, C3 exoenzyme blocked the effect of
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Figure 6. (A) Analysis of ␣v␤3 and
CD44 expression in WT and
OPN⫺/⫺ osteoclasts. Osteoclasts
isolated from OPN⫺/⫺ (lanes 1, 3, 5,
and 7) and WT (lanes 2, 4, 6, and 8)
were surface-labeled with biotin and
immunoprecipitated with either anti-␤3 (lanes 1 and 2) or anti-CD44
(lanes 5– 8) antibodies. Immunoprecipitations with nonimmune serum
(NI) are shown in lanes 3 and 4. Immunoprecipitates (lanes 1– 6) were
blotted with streptavidin-HRP to visualize the surface expression of the
␤3 subunit (lanes 1 and 2) and CD44
(lanes 5 and 6). The CD44 immunoblot (lanes 5 and 6) was stripped and
immunoblotted with anti-CD44 (antibody to the sCD44; BioSource International Inc.) and anti–rat, HRP-conjugated primary and secondary
antibodies, respectively. Only a single band of 85-kDa CD44 protein
was detected in equal amounts in
both OPN-deficient (lane 7) and WT
(lane 8) osteoclast lysates. Arrows
point to the CD44, ␣v, and ␤3 proteins. The results shown are representative of three different experiments. (B) The effect of OPN on
CD44 surface expression. Cell lysates
made from PBS (lanes 1 and 3) or
OPN–treated (lanes 2 and 4) osteoclasts isolated from WT (lanes 1, 2,
and 5) or OPN⫺/⫺ (lanes 3 and 4)
mice were immunoprecipitated with
anti-CD44 (lanes 1– 4) or nonimmune
serum (NI; lane 5). Immunoprecipitates were blotted with streptavidinHRP to visualize the surface expression of CD44 (lanes 1–5, top panel).
The immunoblot shown in the top panel was stripped and blotted with an sCD44 antibody (BioSource International Inc.) to demonstrate the
cellular levels of CD44 immunoprecipitated (bottom panel). The results shown are representative of three independent experiments. (C)
Analysis of CD44 variant expression in osteoclasts. Lysates were made from osteoclasts (lanes 2, 3, 5, and 6) and melanoma cells, a positive
control for CD44 variants (lanes 1 and 4). Immunoprecipitates were prepared using antibodies to CD44s (lanes 1–3; antibody to the sCD44;
BioSource International Inc.) or CD44 v3–10 (lanes 4 – 6; goat polyclonal anti-human CD44 variant, v3–10; BioSource International Inc).
Immunoprecipitates were blotted with streptavidin-HRP to visualize the surface expression of CD44. The arrow indicates the band
corresponding to the size of sCD44. Asterisks indicate the splice variant form of CD44. The results shown are representative of three
independent osteoclast preparations and experiments.

RhoVal14 and decreased the CD44 surface expression level
below basal level in both OPN⫺/⫺ (Figure 7A, lane 4, and
7C) and WT (Figure 7A, lane 8, and 7C) osteoclasts. Figure
7C shows the densitometric scans of three independent experiments were expressed as percentage of CD44 surface
expression. The surface expression level shown in each lane
of Figure 7A was normalized to the corresponding total
cellular levels of CD44 in Figure 7B. The percentage was
calculated by comparing the various treatments of
OPN⫺/⫺ and WT osteoclasts to control, which refers to
PBS-treated wild-type osteoclasts (Figure 7C). RhoVal-14
transduction stimulated CD44 surface expression significantly in OPN⫺/⫺ osteoclasts but the effect was still lower
than the effect observed in OPN-treated or RhoVal-14-transduced (lane 6) osteoclasts isolated from wild-type mice.
These data demonstrate a role for Rho in CD44 surface
expression.
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Role of Rho on Osteoclast Bone Resorption
Because RhoVal-14 transduction increases CD44 surface expression in OPN⫺/⫺ osteoclasts, we analyzed the effects of
Rho proteins on the bone resorption activity of osteoclasts
from WT and OPN-deficient mice (Figure 8). RhoVal-14 transduction (C) had effects similar to OPN (B), and C3 exoenzyme (E) blocked the Rho effects in osteoclasts from both WT
(Figure 8C) and OPN⫺/⫺ (Figure 8I) mice.

The Effects of the Neutralizing Antibodies to OPN,
␤3, and CD44 on OPN-induced Bone Resorption
In Vitro
Osteoclasts derived from WT (Figure 9, top panel) and
OPN⫺/⫺ (bottom panel) mice were plated on dentine slices
and treated as shown in Figure 9. Consistent with our preMolecular Biology of the Cell
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multiple overlapping pits formation by neutralizing antibodies to OPN (Figure 9, C and I), ␤3 (Figure 9, D and J), or
CD44 (Figure 9, F and L) in both WT and OPN⫺/⫺ osteoclasts demonstrate that OPN-induced bone resorption is
dependent on both ␣v␤3 and CD44 receptors. The above
observations identify the critical role of Rho (Figure 8) as
well as ␣v␤3 and CD44 receptors (Figure 9) in osteoclast
function, under the influence of OPN-mediated signaling.

Skeletal Phenotype of the OPNⴚ/ⴚ Mice
The results shown above demonstrate that OPN deficiency
impairs osteoclast CD44 surface expression, motility, and
bone resorption. The question then became whether these
prominent effects on osteoclast function in vitro were related
to a skeletal phenotype in vivo because they predicted a
significant deficiency in osteoclast function.
In our laboratory facility, mutant OPN⫺/⫺ mice were
healthy for at least 18 months and showed normal somatic
development and reproductive capacity, in agreement with
the initial reports of the development of the null mice.
OPN⫺/⫺ mice behaved as expected and appeared to hear
normally upon startling. Skeletal radiographs revealed no
deformity of the long bones and are not shown. Femoral
lengths were not altered, and the club-like deformities reported in the mild TRAP osteopetrotic mutations (Hayman
et al., 1996; Marks, 1989) were absent.

Assessment of Bone Morphology by pQCT

Figure 7. The effects of OPN or TAT-Rho protein transductions on
CD44 surface expression. (A) Osteoclasts isolated from OPN⫺/⫺
(lanes 1– 4) and WT (lanes 5–9) mice were surface labeled with
biotin after various treatments as indicated in the figure. The lysates
were immunoprecipitated with an antibody to CD44. (A) Immunoprecipitates were blotted with streptavidin-HRP to visualize the
surface expression of CD44. (B) The CD44 immunoblot was stripped
and immunoblotted with anti-CD44 and anti-rat, HRP-conjugated
primary and secondary antibodies, respectively. OPN (lanes 2 and
6) and RhoVal14 transduction increases surface expression of CD44 in
both WT and OPN⫺/⫺ osteoclasts. C3 exoenzyme blocked
RhoVal14-induced CD44 surface expression (lanes 4 and 8). (C) Densitometric scans of three experiments expressed as percent control
are shown as mean ⫾. SEM ***p ⬍ 0.0001: OPN, V14 Rho vs. PBS of
WT osteoclasts; **p ⬍ 0.001: OPN, V14Rho vs. PBS of OPN-deficient
osteoclast; #p ⬍ 0.01: C3/V14 Rho vs. V14 rho of WT and OPN
deficient osteoclast; *p ⬍ 0.05: PBS of OPN-deficient osteoclasts vs.
PBS of WT osteoclasts.

vious (Chellaiah et al., 2000b) and above observations (Figures 3 and 8), OPN stimulated the formation of multiple
overlapping pits in both WT and OPN⫺/⫺ osteoclasts (Figure 9, B and H). The increase in the area of pits in OPNtreated osteoclasts is due to increase in the simultaneous
process of motility. The decrease in the OPN effect on the
Vol. 14, January 2003

We analyzed the metaphyses of femurs using pQCT. These
data for 12-week-old mice are summarized in Table 2. Trabecular bone area was significantly increased in the
OPN⫺/⫺ femurs compared with femurs from the wild-type
animals (p ⬍ 0.01). The trabecular mineral density tended to
be higher in OPN⫺/⫺ mice but was not statistically significant. The cortical bone area in the metaphysis of OPN⫺/⫺
mice was greater than that of WT mice (p ⬍ 0.01), but WT
mice had significantly higher metaphyseal cortical bone
mineral density than OPN⫺/⫺ mice (p ⬍ 0.05). Thus, OPN
deficiency was associated with an increase in femoral metaphyseal bone area.

Assessment of Bone Histomorphometry
For assessment of skeletal histomorphometry, mice were
injected with calcein to label areas of bone mineralization on
two occasions and histomorphometry of nondecalcified and
decalcified bone sections was performed as described in
MATERIALS AND METHODS. Tibial metaphyseal sections
were stained or TRAP to aid in detection of osteoclasts. The
trabeculae of OPN⫺/⫺ bones were increased in number
and thickness producing an increase in cancellous bone area
(Table 3) in agreement with the pQCT measurements. Osteoclast number in the metaphyses was higher in bones from
OPN⫺/⫺ mice (Table 3). This increase may have been adaptive for the decreased bone resorption consistent with previous reports (Rittling et al. 1998; Yoshitake et al. 1999). The
intensity of the TRAP stain did not differ between wild-type
and mutant osteoclasts. The decrease in bone resorption of
mutant mice was demonstrated by changes in eroded perimeters. The perimeters of eroded surfaces were significantly reduced in OPN⫺/⫺ mice (p ⬍ 0.05), despite the
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Figure 8. The effects of OPN or
TAT-Rho protein transductions on
bone resorption activity of WT and
OPN-deficient osteoclasts. Osteocalsts isolated from WT and OPN⫺/⫺
mice were treated as mentioned
above each figure. Pits were viewed
under 40⫻ objective in a phase contrast microscope and photographed.
OPN (B and H) and constitutively
active RhoVal-14 (C and J)-stimulated
bone resorption activity compared
with PBS- (A and G) or TAT-TK–
transduced (F and M) control cells.
Dominant negative RhoAsn-14 (D and
K) had no effect. C3 transferase (E
and L) blocked RhoVal-14-induced
bone resorption activity significantly.
The results represent one of the three
experiments performed.

increase in osteoclast number, demonstrating that osteoclast-mediated bone resorption was diminished (Table 3).
The osteoblastic parameters of bone modeling revealed no
change in mineral apposition rate in OPN⫺/⫺ mice, and
bone formation rates were normal (Table 3). Thus, the increase in trabecular bone mass reported here probably resulted from the defect in bone resorption concomitant with
a normal rate of bone formation, producing an imbalance in
skeletal modeling and remodeling similar to that reported in
mild osteopetrotic states (Hayman et al., 1996; Chellaiah et
al., 2000b).

Mechanical Testing of OPNⴚ/ⴚ Femurs
The histomorphometric findings of increased cancellous
bone mass were analyzed further by load to failure testing in
a four-point bending apparatus (Table 4). The OPN⫺/⫺
femora were significantly stiffer (rigidity) and required a
greater energy to produce failure. The cross-sectional moment of inertia was increased. The elastic modulus and
ultimate periosteal tensile stress were increased in the OPNdeficient femurs.

DISCUSSION
The studies reported here demonstrate that OPN is expressed at the clear zone, basolateral and ruffled border
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plasma membrane surfaces of murine osteoclasts. Strongly
positive immunostaining for OPN in newly excavated dentine surfaces demonstrated secretion into the bone resorption space. These data are consistent with those of Dodds et
al. (1995), who demonstrated deposition of OPN into resorption pits on dentine slices, and Maeda et al. (1994), who also
reported that OPN is preferentially present on the resorption
lacunae formed by osteoclasts and that some osteoclasts
trapped OPN on their surfaces.
Because osteoclasts express and secrete OPN, the question
became what if any is the role of OPN in osteoclast function.
We have previously reported that OPN stimulates bone
resorption and osteoclast motility, increasing the number
and depth of resorption pits produced by osteoclasts isolated from WT mice (Chellaiah et al., 2000b). In this study we
demonstrate that osteoclasts from OPN⫺/⫺ mice are hypomotile and less active than WT osteoclasts in bone resorption. Thus, the function of secreted OPN, as an osteoclast
autocrine factor, may be to stimulate cell motility and adhesion related to bone resorption. Osteoclasts are actively migrating cells, and hypomotility decreases bone resorption
(Chellaiah et al., 2000b). Adhesion, organization for migration, and organization for resorption are sequential events
necessary for osteoclast function (Kanehisa and Heersche,
1988), and OPN stimulates each of these events. Also, addition of exogenous OPN to OPN⫺/⫺ osteoclasts rescued
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Figure 9. The effects of neutralizing antibodies to OPN, ␤3, or CD44 on OPN- induced bone resorption. The effects of antibodies to OPN,
␤3, or CD44 were assessed in OPN-induced bone resorption activity of osteoclasts isolated from WT (A–F) and OPN⫺/⫺ (G–L) mice.
OPN-induced bone resorption was reduced when cotreated with antibodies to ␤3 (D and J), CD44 (E and K), or OPN (C and I) in both WT
and OPN⫺/⫺ osteoclasts. Osteoclasts treated with both nonimmune IgG and OPN (F and M) had similar effect as that of OPN-treatment
(B and H). Pits were viewed under 40⫻ objective in a phase contrast microscope and photographed. About three slices were used for each
treatment. The experiment was repeated three times. The results represent one of the three experiments performed.

osteoclast phagokinesis and chemotaxis in vitro. A chemoattractant property of OPN has previously been demonstrated
in macrophage and T-cell migration (O’Regan et al., 1999).
OPN is a unique cytokine in that it stimulates both osteoclast motility and bone resorption. OPN deficiency results
in small, superficial, and simple resorption pits on dentine
slices produced by osteoclasts derived from OPN⫺/⫺ mice.
Stimulation by exogenous OPN increased the pit number
and area formed by OPN⫺/⫺ osteoclasts, but it was not
sufficient to provide for normal resorption pit depth. That
endogenous production of OPN is necessary for normal
bone resorption is consistent with our previous studies
(Chellaiah et al., 2000b) and those of Tani-Ishii et al. (1997),
who demonstrated that treatment of osteoclasts with antiVol. 14, January 2003

Table 2. pQCT of femurs from 12-week-old WT and OPN⫺/⫺
mice
Metaphyseal parameters
Trabecular area (mm2)
Trabecular density (mg/
cm3)
Cortical area (mm2)
Cortical density (mg/cm3)

WT

OPN⫺/⫺

0.72 ⫾ 0.14
286 ⫾ 64

1.66 ⫾ 0.33a
379 ⫾ 28

2.25 ⫾ 0.19
974 ⫾ 47b

2.34 ⫾ 0.22a
818 ⫾ 39

The femoral bone density and area of WT and OPN⫺/⫺ mice were
calculated using a pQCT system as described in MATERIALS AND
METHODS. a p ⬍ 0.01; b p ⬍ 0.05.
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Table 3. Histomorphometry of bones from WT and OPN⫺/⫺ mice
Tibial histomorphometry
Cancellous bone area (%)
Trabecular spacing (m)
Trabecular number (No./mm)
Trabecular thickness (m)
Number of osteoclasts (n)
Osteoclasts/tissue area
(No./mm2)
Eroded perimeter (%)
Mineral apposition rate
(m2/m/day)
Bone formation rate/bpm
(m2/m/day)

WT

OPN⫺/⫺

16.2 ⫾ 2.7
195 ⫾ 38.2
4.79 ⫾ 0.66
28.1 ⫾ 3.61
76 ⫾ 9.7
134 ⫾ 17

29.3 ⫾ 5.3a
98.9 ⫾ 7.6b
6.58 ⫾ 0.44b
55.1 ⫾ 4.68c
97 ⫾ 2.2b
149 ⫾ 12

4.56 ⫾ 0.85
1.50 ⫾ 0.33

1.74 ⫾ 0.69a
1.31 ⫾ 0.14

0.60 ⫾ 0.17

0.54 ⫾ 0.10

Longitudinal sections of the decalcified tibia were made. The sections were stained and the histomorphometric measurements were
performed as described in MATERIALS AND METHODS. Data
shown are means ⫾ SE. There are 4 to 5 animals per group. a p ⬍
0.05; b p ⬍ 0.02; c p ⬍ 0.002.

sense oligodeoxynucleotides to OPN results in inhibition of
bone resorption by mouse osteoclasts in vitro. Moreover,
other investigators have demonstrated inhibition of bone
resorption by anti-OPN antibodies (Udagawa et al., 1996).
The functions of OPN in osteoclasts include the promotion
of cell adhesion during bone resorption (Reinholt et al., 1990)
and chemotaxis (Weber et al., 1996; Weber, 2002). Dephosphorylation of OPN by TRAP may produce detachment of
osteoclasts at the termination of resorption (Ek-Rylander et
al., 1994). Noda et al. (1998) have demonstrated that OPNdeficient bone matrix is poorly resorbed and has the diminished capacity to support cell adhesion to bone. OPN-deficient
osteoclasts are less efficient in removing hydroxyapatite coated
on glass and recruitment to ectopically implanted bone matrix.
Osteopontin purified from bacteria, OPN phosphorylated in
vitro using CKII enzyme, and eucaryotic OPN purified from
human melanoma cells (M21 cells) transfected with OPN
cDNA were added as soluble proteins to OPN⫺/⫺ osteoclasts
plated on dentine slices. These proteins had no effect in increasing the pit depth or rescuing the OPN deficiency in OPN⫺/⫺
osteoclasts despite the fact that these osteoclasts demonstrated
adhesion, polarization, and actin ring formation on dentine

slices. To examine the effects of secretory OPN versus intracellular OPN, osteoclasts isolated from OPN⫺/⫺ mice were either transfected with OPN cDNA or transduced with HATAT/OPN protein, respectively. OPN protein was detected in
the culture medium of osteoclasts transfected with FL-OPN.
An increase in pit depth and CD44 surface expression equal to
wild-type osteoclasts was detected in OPN⫺/⫺ osteoclasts
transfected with OPN cDNA, whereas transduction of HATAT/OPN protein into osteoclasts had no effect in increasing
the pit depth while partially rescuing CD44 surface expression.
Transfection of OPN cDNA rescued OPN deficiency in CD44
surface expression and correcting pit depth (Chellaiah et al.,
unpublished observations). These observations provide evidence to support OPN as a necessary osteoclast autocrine
cytokine, regulating the sequential processes of migration, adhesion, and resorption that occur during bone resorption.
There is general agreement that OPN/␣v␤3 interaction
brings about the osteoclast adherence to the bone surface
(Ross et al., 1993), and the integrin, ␣v␤3 is localized in the
sealing zone of osteoclasts and interacts with OPN in the
bone matrix underneath (Flores et al., 1992; Hughes et al.,
1993; Nesbitt et al., 1993). Studies by Weber et al. (1996) have
shown that OPN can mediate chemotaxis and attachment of
monocytic cells through CD44 receptor. Therefore, we first
studied the surface expression of CD44 and ␤3 receptors in
osteoclasts from WT and OPN⫺/⫺ mice. CD44 surface expression is decreased in OPN-deficient osteoclasts, whereas
the levels of the integrin receptor, ␣v␤3, were equal in both
WT and OPN-deficient osteoclasts. Furthermore, OPN addition stimulated osteoclast chemotaxis through the ␣v␤3 integrin as shown here and previously (Chellaiah et al., 2000a,
2000b). A neutralizing antibody to the integrin, ␤3 blocked
the rescue of CD44 surface expression by OPN demonstrating that signal transduction by ␣v␤3 is required for CD44
surface expression.
To further demonstrate that lack of autocrine stimulated
signal transduction leading to decreased CD44 on the osteoclast surface was the basis of the OPN null phenotype, we
analyzed whether activation of the key step in OPN-stimulated signal transduction would suffice to rescue the OPNdeficient osteoclast disability. We have shown that Rho activation is a critical step in the stimulation of motility by
exogenous OPN (Chellaiah et al., 2000a), and Rho is required
in the intracellular trafficking of CD44 (Chellaiah, unpublished observations). We transduced constitutively active
(RhoVal14) and dominant negative Rho (RhoAsn19) into oste-

Table 4. Mechanical strength of femurs from 12 week, WT and OPN⫺/⫺ mice
Parameter
Rigidity (Nmm/[mm/mm2])
Ultimate moment (Nmm)
Ultimate normalized displacement (mm/mm2)
Energy (Nmmⴱ (mm/mm2)
Cross sectional moment of inertia (mm4)
Elastic modulus (GPa)
Ultimate periosteal tensile stress (MPa)

WT

OPN⫺/⫺

909 ⫾ 70
28.8 ⫾ 3.4
0.042 ⫾ 0.003
0.456 ⫾ 0.12
0.161 ⫾ 0.010
5.7 ⫾ 0.19
116.1 ⫾ 9.5 (n ⫽ 4)

1308 ⫾ 92a
47.3 ⫾ 2.0a
0.047 ⫾ 0.003
1.1 ⫾ 0.08a
0.191 ⫾ 0.008b
7.1 ⫾ 0.62c
170.7 ⫾ 7.9a (n ⫽ 18)

Left femora from WT and OPN⫺/⫺ mice were used for biomechanical testing. Four point bending tests were conducted using a materials
testing machine as described in the MATERIALS AND METHODS. Data shown are means ⫾ SE. a p ⬍ 0.005; b p ⬍ 0.05; c p ⬍ 0.02.
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oclasts and demonstrated that RhoVal14 rescued CD44 surface expression, motility, and bone resorption activity in
OPN⫺/⫺ osteoclasts. The increase in the area of pits generated by RhoVal14 transduced OPN deficient osteoclasts is
indicative of an increase in osteoclast motility function.
Our data regarding osteoclast CD44 are in agreement with
Hughes et al. (1994) and Nakamura et al. (1995) who demonstrated CD44 in human and rat osteoclasts, respectively.
Recent immunocytochemical studies have revealed colocalization of intracellular OPN with CD44 and ERM proteins in
migrating embryonic fibroblastic cells, activated macrophages, and metastatic breast cancer cells. However, this
association was based on OPN binding to an isoform of
CD44 different from that expressed in osteoclasts (Sodek et
al., 2000; Zohar et al., 2000). Thus, it is unclear whether OPN
associates with CD44 during traffic to the membrane in
osteoclasts, but because exogenous OPN was able to rescue
CD44 surface expression in OPN⫺/⫺ osteoclasts, this does
not appear to be a critical association.
The impairment in bone resorption produced in vitro by
OPN deficiency indicated a probable defect in osteoclast
function in OPN-null mutant mice in vivo. Indeed, we found
by histomorphometry an increase in cancellous bone area,
trabecular bone thickness, and a decrease in trabecular spacing compatible with impaired function of osteoclasts in
OPN⫺/⫺ mice. Eroded perimeters of trabeculae were diminished despite increased osteoclast number. It has been
shown that OPN⫺/⫺ mice have increased capacity to make
osteoclasts from spleen cells (Rittling et al., 1998). Our histomorphometric analyses demonstrated that the osteoclast
number was greater in the bones of OPN⫺/⫺ mice compared with WT mice. The increase in osteoclast number may
be compensatory for the decreased activity of OPN⫺/⫺
osteoclasts. The increase in number of osteoclasts may be
due to an increase in RANKL expression in the bones of
OPN⫺/⫺ mice (Yoshitake et al., 1999). The increase in bone
mass was confirmed by pQCT measurements that showed
an increase in trabecular bone area. This indicates that OPN
deficiency, via defective osteoclast-mediated bone resorption, leads to increased bone mass. The mechanical properties of the OPN⫺/⫺ femora demonstrated increased stiffness, requiring greater energy to fracture. Thus, targeting
OPN stimulated bone resorption might strengthen the skeleton.
The defect in OPN-deficient osteoclast function was insufficient to affect endochondral bone growth, and the shortening and clubbing of the femurs reported in some osteopetrotic states was not observed (Marks, 1989; Hayman et al.,
1996). These data are consistent with reports demonstrating
that OPN deficiency impaired activation of osteoclasts in
estrogen deficiency, PTH stimulation, and RANKL stimulation (Yoshitake et al., 1999; Ihara et al., 2001). Although
Rittling et al. (1998) did not report formal bone histomorphometry, an increase in trabecular bone volume was observed by Yoshitake et al. (1999), consistent with our studies.
Thus, the findings reported herein of thickened calcified
trabeculae, delayed resorption, and diminished eroded perimeters demonstrate a mild defect in osteoclast function
that was neither developmentally important nor sufficient to
affect growth, but it was sufficient to increase trabecular and
cortical bone thickness with age. The findings reported here
are similar to the osteopetrosis of gelsolin deficiency (ChelVol. 14, January 2003

laiah et al., 2000b), and they resemble the long-term outcome
of aminobisphosphonate administration to humans, producing a mild imbalance between bone resorption and bone
formation that results in an increase in bone mass (Liberman, 1995; Saag et al., 1998). Osteopetrosis is a heterogenous
group of disorders, which range in severity from lethal to
the very mild disorder as reported here. The milder form of
osteopetrosis has been associated with significant effects on
skeletal mineralization, demonstrating progressive increases
in bone density (Hayman et al., 1996) as observed here by the
increase in trabecular bone density.
Osteopetrotic phenotype was also identified in transgenic
mice developed by disruption of c-Src (Soriano et al., 1991)
or c-Fos gene (Wang et al., 1991). Osteopetrotic phenotype in
these mice are due to either inactive or absence of osteoclasts, respectively. Similarly, the mutation responsible for
the microopthalmic (mi) mouse osteopetrosis has been identified in the gene encoding a novel member of the basichelix-loop-helix-helix leucine zipper (bHLH-ZIP) protein
family of transcriptional factors. A defect in the fusion process of osteoclast precursor cells was detected in these mice
(Chambers and Loutit, 1979; Minkin, 1981). Mice with no
biologically active CSF-1 developed osteopetrotic phenotype
due to almost complete lack of osteoclast and impaired bone
resorption (Naito et al., 1991; Cecchini et al., 1994). In humans, deficiency of carbonic anhydrase II is identified as the
primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification (Sly et al., 1983; reviewed in Felix et al., 1996). These
observations demonstrate the genetic effects of some osteopetrotic mutations and their relevance to the development
and function of osteoclasts. The OPN null mice demonstrate
a milder osteopetritic phenotype due to deficiency in CD44
surface expression resulting in defective motility and bone
resorptive functions of osteoclasts.
Our data show that OPN is a required osteoclast motility
factor mediating surface expression of CD44 receptor. Also,
OPN secreted into the resorption pit is required for adhesion
during bone resorption. Osteoclast-like cells derived from
peripheral blood of osteopetrotic patients and normal individuals demonstrated similar morphology but alterations in
the expression of CD44. These osteoclasts were defective in
bone resorption function (Flanagan et al., 2000). Spatial and
temporal patterns of OPN/CD44 expression were seen in
the healing fractures of rat femora. In the remodeling callus,
CD44 expression was detected on the basolateral plasma
membrane of osteoclasts, osteocyte lacunae but not in the
cuboidal osteoblasts. It was shown that OPN is the major
ligand for CD44 on bone cells in the remodeling phase of
healing fractures and CD44/OPN interaction has clinical
implications in the repair of skeletal tissues (Yamazaki et al.,
1999). The decrease in CD44 expression in osteopetrotic
patients (Flanagan et al., 2000) and in OPN⫺/⫺ mice that are
mildly osteopetrotic implicates the role of CD44 in osteoclast
function and bone modeling. Our data demonstrate the required roles of OPN in osteoclast function and provide new
insights into the role of ␣v␤3 and CD44 receptors in osteoclast function and disordered bone modeling. We have also
demonstrated that OPN/␣v␤3 generated outside-in Rho signaling pathway is required for the surface expression of
CD44 as well as CD44 associated signaling complex formation. Osteoclast motility requires both ␣v␤3 and CD44 recep187
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tors. Surface expression of CD44 can influence multiple
pathways that are crucial for osteoclast motility.

Felix, R., Hofstetter, W., and Cecchini, M.G. (1996). Recent developments in the understanding of the pathophysiology of osteopetrosis.
Eur. J. Endocrinol. 134, 143–156.
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